Research contextSee what supports this page, how current it is, and where comparable or historical context is available.
- Research date
- Sep 21, 2026Use the dated article and cited sources for the definition, examples, and stated limitations.
- Operating-model context
- 16 connected conceptsPart of the reviewed Biopharma Development and Commercialization; issuer definitions remain distinct where disclosed.
- Company examples
- 1 reviewed companyRelationships reflect supported examples, not a normalized cross-company KPI ranking.
A Biologics License Application, or BLA, is a submission seeking FDA authorization to market a biological product in the United States.
FDA describes a BLA as containing information on manufacturing, chemistry, pharmacology, clinical pharmacology, and the product's medical effects.
Why investors track BLAs
A BLA can move a biologic from development into formal regulatory review.
Important events include:
- submission;
- FDA acceptance for filing;
- priority or standard review;
- advisory committee meetings when applicable;
- PDUFA goal dates; and
- final FDA action.
FDA's current CBER guidance notes that standard and priority review timelines are governed by PDUFA goals.
Sources:
A BLA filing starts a marketing-review process. It does not mean the biologic has been approved.
Part of the Biopharma Development and Commercialization
Connect clinical-trial evidence, FDA application and expedited pathways, collaboration economics, gross-to-net commercialization, and loss-of-exclusivity risk to understand drug-development businesses.
How the model fits together
- Clinical evidence and execution: Trial phase frames development maturity, enrollment affects execution timing, primary and secondary endpoints define the prespecified evidence hierarchy, and a readout converts that study design into new evidence for investors to interpret.
- FDA pathway and review milestones: NDA and BLA submissions begin formal marketing review for drugs and biologics, PDUFA dates frame target action timing, and accelerated approval, Breakthrough Therapy, and Orphan Drug designations describe distinct regulatory pathways or incentives rather than approval outcomes.
- Commercialization, partnerships, and exclusivity: Gross-to-net adjustments bridge gross product demand to recognized revenue, royalties and milestones describe partner economics, and patent expiry plus loss of exclusivity frame when legal protection may translate into competitive revenue erosion.
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare stocks
Compare biopharma stocks
Continue into stock comparison for pipeline stage, regulatory milestones, commercialization economics, concentration, and valuation context.
Explore more topics in the Financial Research Encyclopedia.